N/A
N=194
Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department
Respiratory Tract Infections · Influenza, Human · Common Cold
Bottom Line
View on ClinicalTrials.gov: NCT02957136 ↗Enrolled (actual)
194
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Rapid respiratory pathogen nucleic acid amplification test (Device)
- Age
- Pediatric, Adult, Older Adult · 1+ yrs
- Sex
- All
- Sponsor
- University of California, Davis
- Primary completion
- Apr 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED |
20; 33 | — |
| SECONDARY Proportion of Patients With a Respiratory Pathogen Identified |
61; 20 | — |
| SECONDARY Proportion of Patients With a Laboratory-confirmed Influenza Diagnosis |
24; 8 | — |
| SECONDARY Proportion of Patients Receiving Appropriate Anti-influenza Treatment or Prescription |
73; 32 | — |
| SECONDARY Proportion of Patients Discharged Home From the ED Versus Hospital Admission |
69; 66 | — |
| SECONDARY Proportion of Patients With All-cause or Respiratory Illness-related Repeat ED Visit, Hospital or ICU Admission, or Death Within 30 Days |
31; 38 | — |
| SECONDARY Proportion of of Patients With Clinician Adherence to Guidelines for the Treatment of Patients With Influenza (Recommendations for Use of Antivirals Only) |
7; 3 | — |
| SECONDARY Median Length of ED Stay |
4.7; 5.0 | — |
| SECONDARY Median Length of Hospital Stay |
71.2; 54.93 | — |
Summary
This is a randomized clinical trial to assess the effect of rapid, near point-of-care testing for multiple common respiratory viruses and bacteria on antibiotic and anti-influenza medication use in emergency department (ED) patients with symptoms of influenza-like illness (ILI) and/or upper respiratory infection (URI).
Eligibility Criteria
Inclusion Criteria
- University of California, Davis (UC Davis) Emergency Department patients evaluated for influenza like illness and/or upper respiratory infection by an ED physician who consent and agree to have a nasopharyngeal swab collected for the study
- English speaking or Spanish speaking patients
Exclusion Criteria
- Neonates
- Prisoners
- Employees of UC Davis/Students of the Principal Investigator or Co-Principal Investigator
- Non-English, non-Spanish speaking patients
Data sourced from ClinicalTrials.gov (NCT02957136). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.